A number of experts have questioned the clinical validity underlying Interleukin's tests and hope Orig3n will not revive them.
Interleukin said in July that it would liquidate its assets after laying off 63 percent of its workforce and suspending sales of its controversial genetic test.
The American Dental Association wants insurers and test manufacturers to show genetic testing is scientifically valid before they're used to determine coverage eligibility.
The US Food and Drug Administration has preliminarily found that test tubes from Becton Dickinson were not the cause of inaccurate blood-lead test results using Magellan Diagnostics tests and systems.
The announcement comes three weeks after Interleukin said it was laying off 63 percent of its workforce and suspending sales of a controversial genetic test.
Geneticists and periodontists point to financial conflicts, the lack of genetics knowhow, and regulatory gaps for the availability of a test they say should have never come to market.
The decisions are part of the company's restructuring efforts after it was unable to extend deferral of its debt payment with its senior lender.
Interleukin said the reduction in revenues resulted from lower contract research revenue and fewer kits returned for processing related to a promotional product bundle program.